95 results
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
29 Aug 19
RepliCel Life Sciences Retains Dermatology Sales and Marketing Executive to Guide the Global Commercial Strategy for its Automated Dermal Injector
11:47am
Exhibit 99.1
RepliCel Life Sciences Retains Dermatology Sales and Marketing Executive to Guide the Global Commercial Strategy for its Automated … , an aesthetic dermatology product specialist and former executive in several top-tier companies, to help build out the global commercial strategy
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
19 Mar 19
RepliCel Reignites its First-in-Japan Strategy
12:11pm
Exhibit 99.1
RepliCel Reignites its First-in-Japan Strategy
Next-stage trials in Japan present market launch opportunities for RepliCel's skin … "), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce the resumption of their First-in-Japan strategy
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
6 Mar 19
51-102F3 Material Change Report
4:53pm
meeting solidified the analysis and strategic plan. We have emerged from this process with clarity around our strategy that we are eager to communicate … with shareholders and the broader marketplace.
The Company’s core message is this: The Company’s strategy drives the Company toward revenue
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
6 Nov 18
RepliCel Life Sciences Appoints Head of Clinical and Regulatory Affairs
11:03am
has been a valuable consultant to RepliCel since its inception assisting with research, development, clinical and regulatory strategy in addition … for contributing to and executing RepliCel's clinical and regulatory strategy and being the primary clinical/regulatory interface between the Company
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
5 Mar 19
RepliCel CEO Provides 2019 Shareholder Update
10:41am
this process with clarity around our strategy that we are eager to communicate with shareholders and the broader marketplace.
Our core message … is this:RepliCel's strategy drives the Company toward revenue and the Board's objective of minimizing the need for capital and dilution until the Company
6-K
EX-99.1
fq47b pidc
25 Oct 17
Current report (foreign)
12:00am
6-K
EX-99.1
15wg2u8z99adno4ld9
26 Nov 19
RepliCel Provides 2019 Year-End Update
12:41pm
6-K
4l2l prujm
19 Mar 19
RepliCel Reignites its First-in-Japan Strategy
12:11pm
6-K
EX-99.1
09v7m453 xn
16 Nov 21
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
4:03pm
6-K
EX-99.1
791s8pg64a8r5xi02n0d
26 Mar 19
Current report (foreign)
1:45pm
6-K
EX-99.1
bkhs9nhz
10 Sep 19
RepliCel's Partner, YOFOTO (China) Health, Unveils its Inaugural Cell Therapy Manufacturing Facility in China
11:22am
6-K
2h6at64 ocq663l
29 Aug 19
RepliCel Life Sciences Retains Dermatology Sales and Marketing Executive to Guide the Global Commercial Strategy for its Automated Dermal Injector
11:47am
6-K
EX-99.2
7zfp4o bzq4u3ikgbj4
18 Aug 21
Current report (foreign)
12:20pm
6-K
EX-99.1
r08g ipd4o4ore
6 Jun 14
Replicel Life Sciences Inc. 6-K
12:00am
6-K
EX-99.1
4pxn1ntmx6s3x
17 Oct 18
RepliCel Life Sciences Appoints New Chief Financial Officer
10:58am
6-K
EX-99.1
souf1b7ik7a
18 Oct 18
Current report (foreign)
11:03am
6-K
EX-99.1
eus63
7 Jul 22
Statement of Executive Compensation
1:43pm
6-K
EX-99.5
1jze5 vv3k2uhq
18 Aug 21
Current report (foreign)
12:20pm
6-K
EX-99.1
vtim6z6nlhqvo7zb63p2
11 Oct 18
RepliCel Life Sciences Completes Financing with YOFOTO (China) Health
11:45am
6-K
EX-99.2
sz46hd t5v148kr7t
28 Aug 13
Current report (foreign)
12:00am